Key result
Digoxin therapy reveals abnormal serum levels in ~45% of HF patients with Chagas cardiomyopathy.
Why the study?
What is the distribution of digoxin serum levels in patients with Chagas' cardiomyopathy and chronic heart failure?
Cross-Sectional (n=29)
What is the distribution of digoxin serum levels in patients with Chagas' cardiomyopathy and chronic heart failure?
A high proportion of patients with Chagas' cardiomyopathy and heart failure on digoxin therapy have elevated serum digoxin levels, highlighting the need for routine monitoring to prevent toxicity.
Answers are grounded in this paper and cite their sources.
Serum digoxin assessment in Chagas cardiomyopathy HF is feasible; leaves open its clinical utility and optimal targets in this population.
INTRODUCTION: The purpose of this study was to determine digoxin serum concentrations in patients with Chagas' cardiomyopathy with chronic heart failure, because little is known concerning this laboratory test in patients with this condition. METHODS: This study focuses on 29 (29%) out of 101 patients with chronic heart failure secondary to Chagas' cardiomyopathy receiving digoxin therapy. Digoxin was measured by the immune-enzymatic method. RESULTS: New York Heart Association Functional Class III/IV was noted in 13 (45%) patients. The mean potassium serum level was 4.3 ± 0.5 mEq/L, mean creatinine serum levels 1.4± 0.3dg/100ml, and left ventricular ejection fraction 34.7 ± 13.8%. The median digoxin serum level was 1.27 (0.55; 1.79)ng/ml. Sixteen (55%) patients had digoxin serum levels higher than 1.0 ng/ml. Abnormal digoxin serum levels were verified in 13 (45%) patients. Digoxin serum levels correlated moderately with creatinine serum levels (r = 0.39; p < 0.03) and negatively with sodium serum levels (r= -0.38; p= 0.03). CONCLUSIONS: Digoxin serum concentration should be measured in patients with Chagas' cardiomyopathy with chronic heart failure receiving digoxin therapy due to the potential for digoxin toxicity.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (2010) conducted a cross-sectional in Chagas' cardiomyopathy with chronic heart failure (n=29). Digoxin therapy was evaluated on Digoxin serum concentration. In patients with Chagas' cardiomyopathy and heart failure receiving digoxin, the median serum level was 1.27 ng/ml, with 55% having levels >1.0 ng/ml and 45% having abnormal levels.
Synapse has enriched 10 related papers. Consider them for comparative context: